Bicalutamide 150mg

@article{Wellington2012Bicalutamide1,
  title={Bicalutamide 150mg},
  author={Keri David. Wellington and Susan J. Keam},
  journal={Drugs},
  year={2012},
  volume={66},
  pages={837-850}
}
SummaryAlthough equivalence could not be established, progression-free and overall survival durations with bicalutamide were not significantly different from those with surgical or medical castration at a median 6.3 years’ follow-up in the combined results of the two monotherapy studies (n = 480). However, at 12 months’ follow-up, HR-QOL scores for sexual interest and physical capacity were higher in bicalutamide recipients than in men who had been castrated.AbstractBicalutamide (Casodex®) is a… Expand
Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
TLDR
Although neoadjuvant BC therapy did not result in equivalent PRPH-PSA suppression when compared with neoadedjuvant LHRHa alone, there was no difference in biochemical failure rates between cohorts at 50 months' median follow-up. Expand
Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
  • S. Saito
  • Medicine
  • Urology case reports
  • 2020
TLDR
Although the condition is extremely rare, urologists should be aware of CAB-induced organ failures such as those of the lung, kidney and liver, and it should also be noted that urologist should not initially prescribe long-acting Gn-RH. Expand
Androgen Deprivation Therapy for Advanced Prostate Cancer
TLDR
For men with castrate-resistant prostate cancer (CRPC), new treatment options with overall survival benefit are available including combined treatment with abiraterone and enzalutamide, nonhormonal therapies like chemotherapy with docetaxel and cabazitaxel, vaccine, and radium-223. Expand
Simultaneous quantitation of abiraterone, enzalutamide, N‐desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS
TLDR
The LC–MS/MS assay that has been developed will be an essential tool that further defines the pharmacology of the combinations of androgen synthesis or AR‐receptor targeted agents and fulfilled FDA criteria for bioanalytical method validation. Expand
Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
TLDR
The roles of ABCB1 and ABCG2 genetic polymorphisms in the pharmacokinetics of bicalutamide in humans were evaluated and it was found that the ABCB2 c.421C>A polymorphism significantly influenced the plasma levels and pharmacokinetic parameters of bICALutamide, but the c.34G>A did not. Expand
Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age
TLDR
Helical tomotherapy in super-elderly patients with localized and locally advanced prostate cancer had good biochemical control rates without severe late toxicity, and all patients improved with conservative therapy. Expand
Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer.
TLDR
It was concluded that the published methodologies using either HPLC or LC-MS/MS are well suited for the quantification of NSAA inhibitors in various biological fluids to delineate pharmacokinetic data. Expand
A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R–3327G and anabolic activity on skeletal muscle mass & function in castrated mice
TLDR
MK-4541 exhibits an optimum profile as an adjuvant therapy to ADT which may provide potent anti-androgenic activity at the prostate yet protective activity on skeletal muscle and behavior in patients. Expand
Detection of predictive markers for therapeutic stratification of salivary glands tumors.
TLDR
This review represents an overview of the lesions of the salivary glands best characterized in terms of molecular aspects, focusing the attention on those markers and molecular alterations which can be important in the diagnosis as well as in the therapeutic stratification of these tumors. Expand
Bioflavonoid hesperetin overcome bicalutamide induced toxicity by co-delivery in novel SNEDDS formulations: Optimization, in vivo evaluation and uptake mechanism.
  • A. Arya, H. Ahmad, +6 authors A. Dwivedi
  • Chemistry, Medicine
  • Materials science & engineering. C, Materials for biological applications
  • 2017
TLDR
The histopathological study showed that pulmonary fibrosis and alteration in the bowman's by BCT treatment were conquered by co-administration of HSP, and the co-delivery approach may be useful for in vivo management of prostate cancer. Expand
...
1
2
...

References

SHOWING 1-10 OF 69 REFERENCES
Bicalutamide in Advanced Prostate Cancer
TLDR
Bicalutamide, with its once-daily regimen and good tolerability, is an attractive option when combined with a GnRH agonist in patients with advanced prostate cancer who are suitable to receive maximum androgen blockade regimens. Expand
Bicalutamide: in early-stage prostate cancer.
TLDR
On two nonblind, randomised trials, bicalutamide 150 mg/day monotherapy was as effective as medical or surgical castration in terms of overall survival in patients with locally advanced nonmetastatic prostate cancer. Expand
Drug Evaluation Oncologic, Endocrine & Metabolic: Bicalutamide (Casodex™)
TLDR
Results of monotherapy studies reveal that 50 mg of bicalutamide is less effective than castration in patients with advanced disease; Phase III monotherapy Studies are ongoing to compare 150 mg ofbicalutamia with castration. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
TLDR
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
The bicalutamide Early Prostate Cancer Program. Demography.
TLDR
This is the largest randomized clinical trial program to date in local prostate cancer and is expected to provide critical information on the role of bicalutamide as an addition to standard care for patients with local prostate cancers who have received a therapy of curative intent or are candidates for watchful waiting. Expand
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
TLDR
Bicalutamide (150 mg) provides significant benefit in patients with locally advanced prostate cancer, and in previously untreated patients there may be a tumor burden below which endocrine therapy provides no benefit or may even decrease survival. Expand
Bicalutamide Pharmacokinetics and Metabolism
once daily as monotherapy for the treatment of early (localised or locally advanced) nonmetastatic prostate cancer. It is used at a dosage of 50mg once daily in combination with a luteinisingExpand
Bicalutamide: clinical pharmacokinetics and metabolism.
  • I. Cockshott
  • Chemistry, Medicine
  • Clinical pharmacokinetics
  • 2004
TLDR
Bicalutamide is a nonsteroidal pure antiandrogen given at a dosage of 150 mg once daily as monotherapy for the treatment of early (localised or locally advanced) nonmetastatic prostate cancer and has the potential to inhibit CYP3A4 and, to a lesser extent, CYP2C9, 2C19 and 2D6. Expand
Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?
TLDR
In the setting of previously untreated locally advanced disease, pooled mature data from two major studies indicate no significant difference in survival outcome between bicalutamide (‘Casodex’) 150 mg and castration. Expand
...
1
2
3
4
5
...